The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
Daily tasks like banking and food delivery are fully digital, yet healthcare remains outdated. In Nigeria, 47.7% of educated adults self-medicate antibiotics, driving antimicrobial resistance deaths. Digital platforms and GLP-1 weight loss programs offer seamless, compliant solutions.
GLP-1 receptor agonists drive effective weight loss but can accelerate bone and muscle loss in postmenopausal women. Aging naturally reduces muscle mass and bone density, and rapid weight loss amplifies these risks. Protect your health with resistance exercise, adequate protein, and comprehensive monitoring.
GLP-1 medications extend beyond diabetes and weight loss to enhance overall metabolic health. They improve insulin sensitivity, curb chronic inflammation, and optimize cholesterol levels. Patients often report sustained energy and better wellness.
Three suspects face robbery charges after stealing $16,000 worth of GLP-1 weight loss drugs, including Ozempic, Mounjaro, and Trulicity, from a pharmacy delivery in Bensalem, Pennsylvania. Police quickly apprehended the men from New York following a high-speed chase. The incident highlights surging demand for these popular medications.
Prof Jim Mann cautions against broad funding for Wegovy, urging focus on high-risk patients like those with heart disease or diabetes. He emphasizes integrating GLP-1 medications into a national obesity strategy with mandatory nutritional support to prevent weight regain. Early data highlights side effect risks and the need for dietary counseling.
Pharmac is evaluating funding for Wegovy, a GLP-1 receptor agonist, to combat New Zealand's high obesity rates. Weight loss specialist Dr. Gerard McQuinlan says it could save taxpayers billions by preventing diseases like Type 2 diabetes. Experts weigh long-term costs, side effects, and criteria.
The Ozempic hype may fade as a BMJ study shows users regain lost weight within 1.5 years after stopping GLP-1 drugs. These medications reduce appetite but require lifelong use and lifestyle changes for lasting results. Obesity stems from systemic issues like convenience culture and ultra-processed foods, not just willpower.
The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.
